In cancer vaccines, circRNA has been applied to tumor-associated antigens, neoantigens, and non-canonical peptides, with a primary focus on inducing potent antigen-specific CD8<sup>+</sup> T cell immunity and enabling combination immunotherapy approaches. Here, CD8A is linked to neoplasm.